Scholarlink

<p>We evaluated the joint relationship of post-operative C-reactive protein (poCRP) and a tumor immune-cell-score (IS) with overall survival (OS) and CRC-specific survival (CSS) in 680 colorectal cancer (CRC) patients recruited in Germany. CRP was assessed post-surgery while IS was derived from CD3 + /CD8+ cell densities in tumor tissue. Patients were categorized into four <b>C</b>-<b>R</b>eactive protein-<b>I</b>mmune cell <b>S</b>core (CRIS) groups: CRIS-1 (CRP-low/IS-high), CRIS-2 (CRP-low/IS-low), CRIS-3 (CRP-high/IS-high), and CRIS-4 (CRP-high/IS-low). Associations of CRIS with survival were assessed using Cox regression, and quantified by hazard ratios with 95% confidence intervals (HR, 95%CI). Subgroup analysis by presence of non-metastatic disease and time of blood draw in relation to adjuvant chemotherapy were conducted. After a median follow-up of 9.6 (IQR, 4.6–14.6) years, 214 (31.5%) patients died, 140 (20.6%) from CRC. Patients in CRIS-4 category had worse prognosis compared to CRIS-1 category [HR<sub>(95%CI)</sub>: 2.01 (1.32–3.08) and 2.60 (1.57–4.32) for OS and CSS, respectively]. These associations were stronger for non-metastatic disease (OS<sub>HR</sub> = 2.45, CSS<sub>HR</sub> = 4.49), as well as for patients with blood collected after adjuvant chemotherapy (OS<sub>HR</sub> = 4.17, CSS<sub>HR</sub> = 6.62). Integrating post-operative systemic inflammation and tumor immune characteristics may improve prognostic stratification of patients receiving adjuvant chemotherapy for non-metastatic CRC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Predicting colorectal cancer survival by combined c-reactive protein and tumor immune score

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月25日

查看全文
  • Tafirenyika Gwenzi,
  • Durgesh Wankhede,
  • Tanwei Yuan,
  • Megha Bhardwaj,
  • Petra Schrotz-King,
  • Sophie C. Anker,
  • Ben Schöttker,
  • Michael Hoffmeister,
  • Hermann Brenner

摘要

We evaluated the joint relationship of post-operative C-reactive protein (poCRP) and a tumor immune-cell-score (IS) with overall survival (OS) and CRC-specific survival (CSS) in 680 colorectal cancer (CRC) patients recruited in Germany. CRP was assessed post-surgery while IS was derived from CD3 + /CD8+ cell densities in tumor tissue. Patients were categorized into four C-Reactive protein-Immune cell Score (CRIS) groups: CRIS-1 (CRP-low/IS-high), CRIS-2 (CRP-low/IS-low), CRIS-3 (CRP-high/IS-high), and CRIS-4 (CRP-high/IS-low). Associations of CRIS with survival were assessed using Cox regression, and quantified by hazard ratios with 95% confidence intervals (HR, 95%CI). Subgroup analysis by presence of non-metastatic disease and time of blood draw in relation to adjuvant chemotherapy were conducted. After a median follow-up of 9.6 (IQR, 4.6–14.6) years, 214 (31.5%) patients died, 140 (20.6%) from CRC. Patients in CRIS-4 category had worse prognosis compared to CRIS-1 category [HR(95%CI): 2.01 (1.32–3.08) and 2.60 (1.57–4.32) for OS and CSS, respectively]. These associations were stronger for non-metastatic disease (OSHR = 2.45, CSSHR = 4.49), as well as for patients with blood collected after adjuvant chemotherapy (OSHR = 4.17, CSSHR = 6.62). Integrating post-operative systemic inflammation and tumor immune characteristics may improve prognostic stratification of patients receiving adjuvant chemotherapy for non-metastatic CRC.